FIELD: biotechnology.
SUBSTANCE: following is described: a group of inventions including a synthetic oncolytic virus, a pharmaceutical composition for the treatment of a malignant tumor (variants), and a method of treating a malignant tumor in a subject in need. The synthetic oncolytic virus has a lipid nanoparticle containing N1,N3,N5-tris(3-(didodecylamino)propyl)benzene-1,3,5-tricarboxamide (TT3) and a self-amplifying RNA replicon containing the sequence encoding the interleukin (IL)-molecule 12.
EFFECT: invention expands the arsenal of agents aimed at treating a malignant tumor in a subject in need.
17 cl, 5 dwg, 1 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS AND METHODS OF ORGAN-PROTECTIVE EXPRESSION AND MODULATION OF ENCODING RIBONUCLEIC ACIDS | 2019 |
|
RU2803294C2 |
| ANTICANCER COMPOSITION CONTAINING TUMOR-SPECIFIC ONCOLYTIC ADENO VIRUS AND INHIBITOR OF CONTROL POINT OF IMMUNE RESPONSE | 2018 |
|
RU2777523C2 |
| ANTICANCER COMPOSITION CONTAINING A TUMOR-SPECIFIC ONCOLYTIC ADENOVIRUS AND AN IMMUNE RESPONSE CONTROL POINT INHIBITOR | 2018 |
|
RU2740713C1 |
| LIPID NANOPARTICLES | 2021 |
|
RU2837542C1 |
| RNA PARTICLES INCLUDING POLYSARCOZINE | 2019 |
|
RU2792644C2 |
| POLYNUCLEOTIDES CODING INTERLEUKIN-12 (IL12), AND APPLICATIONS THEREOF | 2017 |
|
RU2769316C2 |
| CANCER THERAPY BY COMBINED USE OF ONCOLYTIC SMALLPOX VACCINE VIRUS AND IMMUNE CONTROL POINT INHIBITOR, AND PHARMACEUTICAL COMPOSITION AND COMBINED DRUG FOR USE IN CANCER THERAPY | 2019 |
|
RU2788874C2 |
| ADENOVIRUS CONTAINING ALBUMIN-BINDING SITE | 2015 |
|
RU2711371C2 |
| METHODS AND COMPOSITIONS FOR TUSC2-IMMUNOTHERAPY | 2017 |
|
RU2755903C2 |
| METHOD OF T-CELL ACTIVATION/PROLIFERATION | 2019 |
|
RU2806549C2 |
